Improvement of exertional dyspneoa in patients with <scp>chronic obstructive pulmonary disease</scp> and severe allergic asthma responding to omalizumab-Reference-Cited by-同舟云学术

Improvement of exertional dyspneoa in patients with chronic obstructive pulmonary disease and severe allergic asthma responding to omalizumab

Published:2023-09-13 Issue:12 Volume:53 Page:1298-1301
ISSN:0954-7894
Container-title:Clinical & Experimental Allergy
language:en
Short-container-title:Clin Experimental Allergy

Author:

Pereira Sophie¹,Verhille Juliette¹,Cailliau Emeline²,Bonniaud Philippe³⁴,Devouassoux Gilles⁴⁵,Fry Stéphanie⁴⁶,Guilleminault Laurent⁴⁷,Khayath Naji⁴⁸,Leroyer Christophe⁹,Chenivesse Cécile⁴⁶,Bautin Nathalie⁶^ORCID

Affiliation:

1. Univ. Lille, Service de Pneumologie Immunologie Allergologie Lille France

2. CHU Lille, Biostatistics Department Lille France

3. Department of Pulmonary Medicine and Intensive Care Unit Dijon‐Bourgogne University Hospital, Inserm U1231, Constitutive Reference Center for Rare Pulmonary Diseases, University of Bourgogne‐Franche Comté Dijon France

4. CRISALIS, F‐CRIN Network, INSERM US015 Toulouse France

5. Department of Respiratory Diseases, CIERA, HCL University Claude Bernard Lyon 1 Lyon France

6. Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 ‐ UMR 9017 ‐ CIIL ‐ Center for Infection and Immunity of Lille Lille France

7. Department of respiratory medicine, Toulouse University Hospital, Faculty of Medicine, Toulouse, France. Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051 University Toulouse III Toulouse France

8. Chest Diseases Department Strasbourg University Hospital Strasbourg France

9. CIC INSERM 1412 Université de Bretagne Occidentale Brest France

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cea.14392

Reference9 articles.

1. Update on Asthma–COPD Overlap (ACO): A Narrative Review

2. Adults with asthma treated with add‐on omalizumab report less limitation in activities of daily living;Oliveira JM;J Bras Pneumol,2022

3. Omalizumab treatment and exercise capacity in severe asthmatics – Results from a pilot study

4. Omalizumab Treatment Response in a Population With Severe Allergic Asthma and Overlapping COPD

5. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO